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Abstract
               Hypertrophic cardiomyopathy (HCM) is an important cardiovascular disease with 
sudden   cardiac   death   as  the   most   devastating   presentation.   Implantable   cardioverter 
defibrillators (ICD) are the optimal therapy for prevention of sudden death from ventricular 
tachycardia or fibrillation of any cause.  While there is no controversy with implanting ICDs in 
patients who have already survived a cardiac arrest, identifying high-risk patients for primary 
prevention in this disease remains a challenge. Implanting ICDs in patients with HCM is an 
important clinical consideration since many individuals could achieve normal or near-normal 
lifespans with this protection.                                                                      
Keywords:  Hypertrophic cardiomyopathy; implantable defibrillator; sudden cardiac death
            Hypertrophic cardiomyopathy (HCM) is the most common genetically inherited cardiac 
disorder with an estimated prevalence of 1 in 500 in the general population1. The disease is 
characterised by marked heterogeneity with respect to clinical manifestations, natural history 
and prognosis. Sudden cardiac death (SCD) is the most the devastating consequence of the 
disease and HCM is now recognized as most frequent cause of sudden cardiac death in pre-
adolescent and adolescent children, as well as young athletes. This is not to suggest, however 
that patients who have reached midlife or even beyond are immune from SCD; in fact, no age is 
considered safe from this point-of-view2,3.                                                          
               The causes of sudden death in HCM remain controversial. While earlier theories 
outflow-tract   obstruction,  addressedthe   current   consensus   favors   primary   ventricular 
arrhythmias, while recognising that the pathogenesis of  such  arrhythmias  is  multifactorial  and 
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involve complex interactions between a combination of factors. Given the high liklihood of 
prevention   of   sudden   death   from   ventricular   tachycardia   or   ventricular   fibrillation   by 
implantable cardioverter-defibrillators (ICD) in multiple primary and secondary prevention trials 
of ischemic and non-ischemic dilated cardiomyopathy, it is a reasonable expectation that such 
results can be replicated in patients with HCM. The difference between HCM and coronary 
artery disease is that risk-stratification in HCM with such variable natural history is exceedingly 
difficult and there exists no definitive consensus on precisely which patients should receive an 
ICD for primary prevention. On the other hand the ICD is strongly indicated for any patient, 
including those with HCM, who has survived a documented cardiac arrest i.e.,  secondary 
prevention4,5.
            It is important to remember that unlike other patients with ischemic or non-ischemic 
cardiomyopathy and ICD implants who have a limited life-span owing to advanced congestive 
heart  failure  and  age,  high  risk  HCM  patients  are  usually  younger   and  asymptomatic. 
Consequently, the potential of the ICD to prolong life is much greater in the HCM population, 
and therefore it is vitally important that patients be identified correctly for this therapy. In  order 
to create a high risk profile, all HCM patients should undergo an initial comprehensive 
ambulatory risk stratification assessment, including detailed personal and family history and 
physical   examination,   12-lead   ECG,   echocardiogram,   ambulatory  Holter   monitoring   and 
exercise testing. The currently recognised major risk factors for SCD in HCM include: 
unexplained syncope, (particularly when exertional or recurrent), family history of HCM-related 
sudden death, identification of high-risk mutant genes, frequent, multiple or prolonged  episodes 
of   non-sustained  ventricular   tachycardia  on  Holter   monitoring,  abnormal   blood  pressure 
response to exercise and extreme degrees of left ventricular hypertrophy (maximum  left 
ventricular wall thickness of 30 mm or more), particularly in adolescents and young adults6. 
Invasive electrophysiology study as a means of risk stratification has been largely abandoned in 
HCM patients, primarily because of the unknown clinical significance of commonly induced 
ventricular tachyarrhythmias in the laboratory.                                                                   
            Controversy exists as to how many major risk factors are required in a particular patient 
to be considered deserving of an ICD, and some of this is uncertainty is due to the fact that the 
magnitude of risk conferred by each risk marker may not be the same. While the presence of 
multiple risk factors may convey an increased risk, a single risk factor may be adequate in a 
given patient to justify an ICD implant. ICD trials in HCM have documented their efficacy for 
sensing and terminating arrhythmias. A recent study by Maron, et al.  showed appropriate 
discharges triggered by VT in 23% of patients when followed over 3 years, with an average 
discharge rate of 5% per year for primary prevention and 11% per year for secondary 
prevention.  About  60%   of   the  patients  with  appropriate  interventions  received  multiple 
discharges7. 
            There are certain technical considerations for the electrophysiologist implanting ICD's in 
this population that deserve mention. The first relates to whether a single- or dual-chamber 
system should be employed. Dual chamber devices have the benefit of AV synchrony with 
pacing, although for the most part pacing as a treatment modality in HCM to reduce symptoms 
and outflow gradient was largely abandoned after the M-PATHY trial8. More importantly, dual 
chamber devices provide superior SVT discrimination. The latter is particularly important in this 
population which has   a high incidence of atrial fibrillation, though newer technology  (for 
morphology, stability and onset discrimination) may provide relatively good discrimination even 
with single lead systems. The single-chamber "shock box" device is probably a more appropriate 
option for young patients who do not appear susceptible to atrial fibrillation and in whom 
survival depends largely on effective ventricular arrhythmia termination. A single chamber ICD 
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is also indicated in all patients with chronic atrial fibrillation, while patients with paroxysmal 
atrial fibrillation would probably benefit more from dual chamber devices with mode-switch 
capability. It should be  emphasized that atrial fibrillation may be poorly tolerated in HCM 
patients who already have severe diastolic dysfunction since LV filling is critically dependent on 
effective atrial systole. A dual chamber device with rate-drop response is probably a better 
option for a HCM patient with recurrent episodes of neurocardiogenic syncope, although trials 
of pacing for neurocardiogenic syncope have so far provided ambiguous results. An excellent 
update on selection of ICDs for each patient has been published recently9.                                       
            Lead fractures and device recalls are particularly relevant events that affect young HCM 
patients who will likely spend their whole lives with the ICD system. Unfortunately, these are 
impossible to predict in advance, and lead removal, in particular for older leads, is fraught with 
difficulties10. Whenever possible, adding a new lead should be  preferred to extracting an old 
one. Though active fixation leads that are less than 6-months old are usually removed without 
difficulty, passive leads require laser excision and should only be performed in a center with 
considerable experience with such procedures.                                                        
            The number of HCM patients who meet criteria for an ICD implant is increasing. It 
behoves the cardiovascular community to offer these patients all major advances in treatment so 
that they can continue to lead productive lives, given their preserved systolic function and often 
minimum symptoms. Many of the current uncertainties about patient selection will be resolved 
soon with further clinical trials, and in the future more HCM patients will live longer lives with 
the aid of more technologically advanced ICD systems.                                         
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